-
Frequency of EGFR-TKI resistant or co-exiting<sup>*</sup> mutations.
Frequency of EGFR-TKI resistant or co-exiting* mutations. -
Molecular testing and treatment patterns for patients with advanced non-small...
BackgroundThe goals of this multinational retrospective study were to describe treatment patterns and survival outcomes by receipt of molecular testing and molecular status of... -
r37980778c78--7ec636573ca61b3cd55b536f81eaa1fc
Analysis of relationships between vimentin and clinicopathological variables in NSCLC. -
r37980778c78--c364e66c552cfc7356ffa91494948e54
The baseline characteristics in patients based on PD-L1 expression level. -
Estimate of overall survival considering the clinical variables and plasma le...
Estimate of overall survival considering the clinical variables and plasma level of IL-6. -
Demographic and clinical characteristics of patients by receipt of one or mor...
Demographic and clinical characteristics of patients by receipt of one or more molecular testsa (yes/no) in Japan, Korea, Taiwan, and Brazil. -
r37980778c78--ce343bb5c2fe0d63e8978bffee4fa384
Clinical outcomes of pembrolizumab monotherapy according to PD-L1 expression level. -
ADC Histogram Parameters of Pathologic Grades of NSCLC.
ADC Histogram Parameters of Pathologic Grades of NSCLC. -
r37980778c78--b979a9056112b249b287eaccecfe77cc
Cytokine expression levels between NSCLC patients and healthy subjects. -
r37980778c78--fe800cb4e92007f8f9ae6596361ba8b6
Studies evaluating treatment patterns in patients with advanced non-small cell lung cancer by country. -
Overall survival by NSCLC histology, predictive biomarker testing, and mutati...
Overall survival by NSCLC histology, predictive biomarker testing, and mutation status (EGFR mutation and/or ALK rearrangement). -
Subgroup analysis of HR in overall survival (OS) by univariate and multivaria...
Subgroup analysis of HR in overall survival (OS) by univariate and multivariable analyses. -
FIR from in vitro, ex vivo and in vivo pCLE assessment of apoptosis using C3-...
FIR is given for experiments using C3-NucView pCLE of A549, H460, H1975, H1650 and HCC827 cell lines (in vitro) and tumor xenografts (ex vivo and in vivo). VEH: vehicle. CDDP:... -
r37980778c78--5a7fbe536e9eb36b0c4909ea626334d4
BackgroundPembrolizumab is currently approved as a first-line therapy for advanced non-small cell lung cancer (NSCLC) patients with a programed death ligand-1 (PD-L1) expression... -
List of features of each patient whose tumors harbored EGFR TKI resistant mut...
List of features of each patient whose tumors harbored EGFR TKI resistant mutations. -
Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyr...
IntroductionComparison of the effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors (TKIs) would improve patients’ clinical benefits and save... -
Mediastinal lymph-node puncture rates according to station (study Step 1).
Mediastinal lymph-node puncture rates according to station (study Step 1).
